Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
- Details
- Category: Novartis

Pfizer and BioNTech granted FDA Fast Track designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2
- Details
- Category: Pfizer

Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
- Details
- Category: Sanofi

GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
- Details
- Category: GlaxoSmithKline

Merck initiates first clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of COVID-19 infection
- Details
- Category: Merck Group

Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US
- Details
- Category: Novartis

Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2
- Details
- Category: Pfizer

More Pharma News ...
- Lilly begins world's first study of a potential COVID-19 antibody treatment in humans
- GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials
- Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
- Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
- Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
- Bayer supports "The Challenge Initiative" of Johns Hopkins Bloomberg School of Public Health with 10 million USD
- Sanofi invests to make France its world class center of excellence in vaccine research and production